KU812_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
CML · Chronic Myelogenous Leukemia
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- CML
- cancer_type_detailed
- Chronic Myelogenous Leukemia
- subtype
- —
- cancer_type
- CML
- ccle_sample_id
- KU812_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE
- synthetic_from_ccle
- true
- display_name
- KU812
- ccle_lineage
- blood
- ccle_lineage_subtype
- CML
- ccle_lineage_sub_subtype
- blast_crisis
- oncotree_code
- CML
- cancer_type_detailed
- Chronic Myelogenous Leukemia
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- HEME_METABOLISM+1.729
- MYC_TARGETS_V2+0.758
- MYC_TARGETS_V1+0.514
- G2M_CHECKPOINT+0.347
- E2F_TARGETS+0.304
- ALLOGRAFT_REJECTION+0.252
- DNA_REPAIR+0.201
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.163
- UNFOLDED_PROTEIN_RESPONSE+0.156
- FATTY_ACID_METABOLISM+0.156
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.636
- NOTCH_SIGNALING-0.447
- TNFA_SIGNALING_VIA_NFKB-0.439
- GLYCOLYSIS-0.420
- MYOGENESIS-0.392
- TGF_BETA_SIGNALING-0.377
- CHOLESTEROL_HOMEOSTASIS-0.367
- HYPOXIA-0.330
- ANGIOGENESIS-0.324
- APICAL_JUNCTION-0.320
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
4 twins match this tumor's tissue · 6 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MOLM16_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.958 |
| 2 | MEG01_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | CML | — | 0.946 |
| 3 | HEL_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.930 |
| 4 | M07E_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.924 |
| 5 | CMK_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.883 |
| 6 | NCO2_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | CML | — | 0.871 |
| 7 | HEL9217_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.852 |
| 8 | TF1_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | AML | — | 0.852 |
| 9 | KYO1_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | CML | — | 0.771 |
| 10 | JURLMK1_HAEMATOPOIETIC_AND_LYMPHOID_TISSUE | CML | — | 0.726 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| HEME_METABOLISM | 1.729 | Temsirolimus | — uncovered |
| MYC_TARGETS_V2 | 0.758 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.514 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.347 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.304 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.252 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.201 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.163 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.156 | Idelalisib | — uncovered |
| FATTY_ACID_METABOLISM | 0.156 | Inavolisib | — uncovered |
| PEROXISOME | 0.130 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.060 | Remibrutinib | — uncovered |
| IL2_STAT5_SIGNALING | 0.032 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.016 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.016 | Inavolisib | — uncovered |